Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors

NCT01520389 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT01520389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01520389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
January 31, 2016
Enrollment
112 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal cancer, non small cell lung cancer, squamous cell head and neck cancer, triple negative breast cancer